43153-12-4

Usage

Uses

Used in the Food and Beverage Industry:
Ethyl (4-formylphenyl)acetate is used as a flavoring agent for its fruity aroma, enhancing the taste and smell of various food and drink products.
Used in the Perfume and Fragrance Industry:
Ethyl (4-forMylphenyl)acetate is utilized as a key ingredient in the production of perfumes and fragrances, contributing to their pleasant and appealing scents.
Used in the Production of Scented Products:
Ethyl (4-formylphenyl)acetate is employed in the creation of a wide range of scented products, capitalizing on its aromatic properties to provide a pleasant olfactory experience.

Upstream product

• 1528-41-2 ethyl 4-cyanophenylacetate 
• 87199-17-5 4-formylphenylboronic acid, 
• 105-36-2 ethyl bromoacetate 
• 7398-81-4 (4-bromomethylphenyl)acetic acid ethyl ester 
• 118618-41-0 [4-(hydroxymethyl)phenyl]acetic acid ethyl ester 
• 50-00-0 formaldehyd 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 113520-36-8 2-(4-(2-ethoxy-2-oxoethyl)phenyl)acetic acid 
• 1122-91-4 4-bromo-benzaldehyde 
• 105-53-3 diethyl malonate 

Downstream Products

• 34841-47-9 2-(4-formylphenyl)acetic acid 
• 118618-41-0 [4-(hydroxymethyl)phenyl]acetic acid ethyl ester 
• 56066-91-2 4-chloromethylphenylacetic acid 
• 669002-79-3 ethyl (4-pyrrolidin-1-ylmethyl-phenyl)-acetate 
• 1612896-27-1 ethyl 2-(4-((phenylamino)methyl)phenyl)acetate 

Relevant academic research and scientific papers

A new class of cytotoxic agents targets tubulin and disrupts microtubule dynamics

Despite the advances in treatment strategies, cancer is still the second leading cause of death in the USA. A majority of the currently used cancer drugs have limitations in their clinical use due to poor selectivity, toxic side effects and multiple drug resistance, warranting the development of new anticancer drugs of different mechanisms of action. Here we describe the design, synthesis and initial biological evaluation of a new class of antimitotic agents that modulate tubulin polymerization. Structurally, these compounds are chalcone mimics containing a 1-(1H-imidazol-2-yl)ethan-1-one moiety, which was initially introduced to act as a metal-binding group and inhibit histone deacetylase enzymes. Although several analogues selectively inhibited purified HDAC8 with IC50 values in low micromolar range, tissue culture studies suggest that HDAC inhibition is not a major mechanism responsible for cytotoxicity. The compounds demonstrated cell growth inhibition with GI50 values of upper nanomolar to low micromolar potency with significant selectively for cancer over normal cells. Interestingly, several compounds arrested HeLaM cells in mitosis and seem to target tubulin to cause mitotic arrest. For example, when combined with inhibitors of Aurora B kinase, they led to dramatic disassembly of the mitotic spindle. In-vitro tubulin polymerization studies showed that the compounds reduced the rate of polymerization of microtubules during the elongation phase and lowered the amount of polymerized tubulin during the plateau phase. Finally, in silico docking studies identified binding of IPE-7 to the colchicine site with similar affinity as the test compound D64131. These compounds represent a new antimitotic pharmacophore with limited HDAC inhibitory activity.

PHENYLETHYLPYRIDINE DERIVATIVES AS PDE4-INHIBITORS

The invention relates to novel compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

NOVEL COMPOUNDS

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstru

QU1NOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA

The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

Water works: An efficient palladium-catalyzed cross-coupling reaction between boronic acids and bromoacetate with aminophosphine ligand

Water greatly restrained the formation of self-coupling of boronic acids in a palladium-catalyzed cross-coupling reaction between boronic acids and ethyl bromoacetate with an aminophosphine ligand; good to excellent yields of cross-coupling product were obtained.

Photolytic decarboxylation of α-arylcarboxylic acids mediated by HgF2 under a dioxygen atmosphere

Mercuric fluoride (HgF2), as a light-sensitive inorganic compound, in the presence of dioxygen is able to convert various α-aryl- and α,α-diarylcarboxylic acids into the corresponding aldehydes and ketones selectively under photoirradiation via trapping of the benzylic radical by O2.

Synthesis of arylacetic acid derivatives from diethyl malonate using in situ formed palladium(1,3-dialkylimidazolidin-2-ylidene) catalysts

The in situ prepared three component system Pd(OAc)2/1,3- bis(alkyl) imidazolinium halide LHX (1-5)/Cs2CO3 catalyses the arylation of diethyl malonate efficiently with accompanying dealkoxycarbonylation. Imidazolinium salts with bulky benzyl and alkoxyethyl groups were found to be the most efficient and afforded α-arylacetates in high yields when employing a wide variety of substrates.

Pd-catalyzed synthesis of arylacetic acid derivatives from boronic acids

A palladium(0)-catalyzed cross-coupling reaction between arylboronic acids or esters and α-bromoacetic acid derivatives is described which allows the synthesis of various functionalized arylacetic acid derivatives under mild conditions.

Quinolin-2-(1H)-ones

PCT No. PCT/EP97/00084 Sec. 371 Date Jul. 17, 1998 Sec. 102(e) Date Jul. 17, 1998 PCT Filed Jan. 10, 1997 PCT Pub. No. WO97/26244 PCT Pub. Date Jul. 24, 1997The invention relates to quinoline-2-(1H)-one derivatives of the general formula I in which R1, R2